| Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL). (NCT07624799) | French Innovative Leukemia Organisation | 2026-09-01 |
| Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy. (NCT07463768) | French Innovative Leukemia Organisation | 2026-09-01 |
| Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients (NCT07007052) | French Innovative Leukemia Organisation | 2025-12-11 |
| Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia (NCT06547866) | French Innovative Leukemia Organisation | 2025-12-01 |
| OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia (NCT06377579) | French Innovative Leukemia Organisation | 2024-07-31 |
| Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome (NCT06186648) | French Innovative Leukemia Organisation | 2024-03-21 |
| Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (NCT06022003) | French Innovative Leukemia Organisation | 2024-01-13 |
| Prognostic Analyses on a Validation Series of Patients With Waldenström's Disease (NCT05911802) | French Innovative Leukemia Organisation | 2023-08-11 |
| REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy (NCT05621148) | French Innovative Leukemia Organisation | 2023-01-25 |
| French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings (NCT05590702) | French Innovative Leukemia Organisation | 2022-11-11 |
| Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission (NCT04968015) | French Innovative Leukemia Organisation | 2022-05-25 |
| Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm (NCT04992949) | French Innovative Leukemia Organisation | 2022-03-23 |
| STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia (NCT04963946) | French Innovative Leukemia Organisation | 2021-10-18 |
| A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE (NCT05193448) | French Innovative Leukemia Organisation | 2021-07-05 |
| Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19 (NCT04452604) | French Innovative Leukemia Organisation | 2020-09-11 |
| Observatory of Prolymphocytic Leukemia T (NCT04411043) | French Innovative Leukemia Organisation | 2020-07-01 |
| COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias (NCT04416438) | French Innovative Leukemia Organisation | 2020-05-18 |
| Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19 (NCT04391946) | French Innovative Leukemia Organisation | 2020-03-14 |
| Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia (NCT04010968) | French Innovative Leukemia Organisation | 2019-09-27 |
| BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation (NCT03931642) | French Innovative Leukemia Organisation | 2019-07-05 |
| Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A (NCT03766763) | French Innovative Leukemia Organisation | 2019-05-22 |
| Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction (NCT03734198) | French Innovative Leukemia Organisation | 2018-12-19 |
| Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy (NCT03603795) | French Innovative Leukemia Organisation | 2018-10-11 |
| Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML) (NCT03609060) | French Innovative Leukemia Organisation | 2018-08-24 |
| Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL (NCT03502876) | French Innovative Leukemia Organisation | 2017-11-02 |